Schenck and coworkers conjugated two commercial antibodies, which are severally anti-PD-L1 for blocking the immune checkpoint on tumor cells and anti-41BB for enhancing the costimulatory signal on T cells, to the antibiotin-coated iron-dextran particles and obtained the injectable immunoswitch nanoparticles (Figure 3A). Here, CD274 is linked to neoplasm.